Molecular Screening & Therapeutics (MoST) Study

The MoST study uses the power of genomic technology to characterize molecular changes in patient's cancer that may help to identify a targeted therapy.

Participation process

MoST has a number of different screening populations

Our program to covers all different types of cancers:

Pan cancer subprogram (MoST and AYA-MoST):

  • for patients, including Adolescents and Young Adults (AYA), with pathologically confirmed advanced or metastatic solid cancers of any histological type, either during or after their last line of effective therapy.

Lung cancer subprogram (ASPiRATION):

  • for adults with newly diagnosed, pathologically confirmed metastatic non-squamous non-small cell lung cancer (mNSCLC), with sufficient and accessible tissue for molecular screening.

Leukaemia and lymphoma subprogramĀ  (MoST-LLy):

  • for patients with advanced blood cancers without an established therapeutic option.

MoST has two stages

Stage 1

We use genomic profiling to analyse the molecular characteristics of a patient’s tumour, we gather as much genetic and clinical information as we can to help us identify specific characteristics about the tumour.

A team of experts review the molecular profile of the tumour with other clinical and patient information. A report is provided to the referring clinician.

Stage 2

Patients identified as possessing any of a range of molecular characteristics (identified during Stage 1) may be eligible to access treatment in a MoST therapeutic study (a clinical trial) or other targeted therapy.

Who can participate in MoST?

Pan cancer subprogram: Patients aged 16yrs and older with an advanced and/or metastatic solid or blood cancer with limited treatment options, and who are willing and fit enough to participate in a clinical trial, are eligible.

Lung cancer subprogram: Patients aged 18yrs and older with newly diagnosed metastatic non-squamous non-small cell lung cancer (mNSCLC),who have not had any previous treatment for the lung cancer and who are willing and fit enough to participate in a clinical trial, are eligible.

Your treating oncologist will assess your eligibility, complete the MoST referral forms, and provide all relevant information.

What does participation involve?

For patients

  • Discussing the study with the MoST team (either by telephone or face-to- face)
  • Consenting to the access of samples held by pathology centres
  • Consenting to the access of their medical records
  • Donating a blood sample
  • Completing questionnaires
  • Optional consent for access for Medicare / PBS data

 

 

Want to know more about MoST

For more information, please email most@agcmc.org or most@garvan.org.au or call (02) 9355 5874.

MoST therapeutic studies

Read more about our studies

Interested in knowing more?

Get in touch